Humans of AI3SD: Jules Tilly
Humans of AI3SD: Jules Tilly
This interview forms part of our Humans of AI3SD Series.
In this Humans of AI4SD interview he discusses his varied career, life as a PhD researcher in a startup, the challenges of working with quantum systems and his advice for early career researchers.
AI3SD, Interview
University of Southampton
Tilly, Jules
885d18cb-c880-4643-9d6f-0adf44a968a7
Pauli, Michelle
ba2e52e9-984d-47c6-b32b-c6ff10db9542
Frey, Jeremy G.
ba60c559-c4af-44f1-87e6-ce69819bf23f
Kanza, Samantha
b73bcf34-3ff8-4691-bd09-aa657dcff420
Niranjan, Mahesan
5cbaeea8-7288-4b55-a89c-c43d212ddd4f
11 August 2022
Tilly, Jules
885d18cb-c880-4643-9d6f-0adf44a968a7
Pauli, Michelle
ba2e52e9-984d-47c6-b32b-c6ff10db9542
Frey, Jeremy G.
ba60c559-c4af-44f1-87e6-ce69819bf23f
Kanza, Samantha
b73bcf34-3ff8-4691-bd09-aa657dcff420
Niranjan, Mahesan
5cbaeea8-7288-4b55-a89c-c43d212ddd4f
Tilly, Jules and Pauli, Michelle
,
Frey, Jeremy G., Kanza, Samantha and Niranjan, Mahesan
(eds.)
(2022)
Humans of AI3SD: Jules Tilly
(Humans-of-AI3SD, 34)
University of Southampton
7pp.
(doi:10.5258/SOTON/AI3SD0231).
Record type:
Monograph
(Project Report)
Abstract
This interview forms part of our Humans of AI3SD Series.
In this Humans of AI4SD interview he discusses his varied career, life as a PhD researcher in a startup, the challenges of working with quantum systems and his advice for early career researchers.
Text
Humans_of_AI3SD_Interview-34_JT
- Version of Record
More information
Published date: 11 August 2022
Additional Information:
Jules Tilly specialises in developing quantum machine learning methods for drug discovery with a focus on optimising algorithm implementation on current / NISQ Quantum Computers. He is a Quantum Research Scientist at Rahko, and is currently completing his PhD at UCL. Prior to this, Jules worked for 6+ years in �nancial services acting as regulatory and strategic advisor for top global investment banks. He holds degrees in Mathematics, Quantum Physics, Law, Economics, Finance and Public Policy. Rahko was acquired by Odyssey Therapeutics, a biotech company pioneering next generation precision immunomodulators and oncology medicines. Read more about Odyssey's mission here [https://odysseytx.com/]
Keywords:
AI3SD, Interview
Identifiers
Local EPrints ID: 469315
URI: http://eprints.soton.ac.uk/id/eprint/469315
PURE UUID: 3b375a2f-b07d-4768-a5a8-e57c1eee60f6
Catalogue record
Date deposited: 13 Sep 2022 16:41
Last modified: 17 Mar 2024 03:52
Export record
Altmetrics
Contributors
Author:
Jules Tilly
Author:
Michelle Pauli
Editor:
Mahesan Niranjan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics